Loading…
Caris Life Sciences, Inc. is projected to rise to $17.56 by 2027, a +3% move from its current price of $16.99. CAI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $16.49 | $17.00 | $17.53 | +0.06% |
| Jul 14 | $16.29 | $17.01 | $17.76 | +0.12% |
| Jul 15 | $16.14 | $17.02 | $17.95 | +0.17% |
| Jul 16 | $16.01 | $17.03 | $18.11 | +0.23% |
| Jul 17 | $15.91 | $17.04 | $18.25 | +0.29% |
| Jul 18 | $15.81 | $17.05 | $18.38 | +0.35% |
| Jul 19 | $15.73 | $17.06 | $18.50 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.73 | $17.06 | $18.50 | +0.41% |
| Week 2 | $15.27 | $17.13 | $19.21 | +0.81% |
| Week 3 | $14.94 | $17.20 | $19.80 | +1.22% |
| Week 4 | $14.68 | $17.27 | $20.31 | +1.63% |
| Week 5 | $14.46 | $17.34 | $20.79 | +2.05% |
| Week 6 | $14.27 | $17.41 | $21.24 | +2.46% |
| Week 7 | $14.10 | $17.48 | $21.67 | +2.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Caris Life Sciences, Inc. is an artificial intelligence TechBio company that provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information and artificial intelligence/machine learning algorithms.
Its molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers.
The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI trades at $17.32 with a market cap of $4.9B and is ranked 1382 in market position. The description places it in Healthcare. The current price sits near its 2026 forecast, with the outlook showing a path of gradual growth and a long-term bullish trajectory according to year-by-year estimates.
The forecast for 2026 centers around a flat start relative to today, with substantial upside emerging toward 2029 and accelerating into 2050, culminating in a high forecast max of $228.54 and an avg of $107.21 in 2050, implying a potential long-run upside even as the near term remains tighter.
In 2026 the average price is $17.32 with a min of $14.55 and a max of $23.87 and a 0% ROI, signaling a neutral near-term view. The forecast progresses with a bullish tilt from 2029 onward, delivering higher average prices and positive ROIs through 2030 ($27.29 avg, 57.6% ROI) and beyond, with a peak around 2050 of $107.21 avg and $228.54 max (ROI 519%).
A major floor 18.8% below — a decisive break under it would weaken the trend.
The nearest floor, 8.9% below — buyers have tended to step in here.
The nearest ceiling, 10.4% above — a clean break opens room to run.
A major ceiling 25.0% above — clearing it would confirm fresh momentum.
Key CAI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CAI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.49 | Sell | $17.51 | Sell |
| MA 10 | $17.91 | Sell | $17.71 | Sell |
| MA 20 | $17.97 | Sell | $17.69 | Sell |
| MA 50 | $17.17 | Sell | $17.78 | Sell |
| MA 100 | $18.20 | Sell | $19.04 | Sell |
| MA 200 | $22.76 | Sell | $21.63 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.17 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -177.92 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -3.47 | Sell |
| Bollinger %B (20,2) | -0.03 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | 0.21 | Buy |
| Ultimate (7,14,28) | 40.95 | Neutral |
| Momentum (10) | -1.71 | Sell |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 17.20 | Sell |
| ADX (14) | 9.24 | Neutral |
| ATR (14) | 0.52 | Info |
The 30-day technical picture is neutral. RSI14 stands at 50 and the near-term moving averages show a SMA50 of $17.24 and a SMA200 of $22.91. Immediate support sits at $15.38 and resistance at $18.75, framing a 30-day range from $14.20 to $21.12. These indicators point to a balanced short-term posture without a clear breakout or breakdown.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.55 | $16.99 | $23.28 | 0% | Neutral | |
| $13.42 | $17.56 | $24.62 | +3% | Neutral | |
| $14.26 | $19.46 | $28.68 | +15% | Neutral | |
| $16.34 | $23.10 | $35.38 | +36% | Bullish | |
| $17.44 | $25.44 | $40.24 | +50% | Bullish | |
| $19.33 | $29.03 | $47.22 | +71% | Bullish | |
| $19.87 | $30.66 | $51.13 | +80% | Bullish | |
| $18.92 | $29.96 | $51.08 | +76% | Bullish | |
| $18.95 | $30.77 | $53.55 | +81% | Bullish | |
| $19.42 | $32.29 | $57.28 | +90% | Bullish | |
| $26.19 | $48.68 | $93.40 | +187% | Bullish | |
| $41.83 | $92.95 | $199.51 | +447% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.55 | $16.99 | $20.57 | +0.00% |
| August 2026 | $14.81 | $17.69 | $21.85 | +4.12% |
| September 2026 | $14.84 | $17.91 | $22.47 | +1.25% |
| October 2026 | $14.28 | $17.38 | $22.09 | -2.95% |
| November 2026 | $14.18 | $17.39 | $22.34 | +0.07% |
| December 2026 | $14.53 | $17.94 | $23.28 | +3.14% |
Click any year to see its month-by-month CAI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CAI price prediction for 2026 points to an average of $16.99 (low $14.55, high $23.28) — a potential gain of 0% on today's $16.99. Price action looks broadly range-bound.
In 2027, CAI is projected to trade between $13.42 and $24.62, averaging $17.56 — a potential gain of +3% from today's $16.99. That is up +3% on the projected 2026 average. A consolidation phase looks the most probable path here.
Caris Life Sciences, Inc.'s 2028 outlook centres on $19.46, within a $14.26 to $28.68 range. That is up +11% on the projected 2027 average. That marks a +15% change versus current levels. Price action looks broadly range-bound.
By 2029, CAI could reach as high as $35.38, with a base case around $23.10 and support toward $16.34 — roughly +36% from $16.99. Buyers look set to stay in control over this stretch.
Expect CAI to range from $17.44 to $40.24 through 2030. The $25.44 average target implies a +50% move from current prices. That is up +10% on the projected 2029 average. Momentum favours further upside here.
The CAI price prediction for 2031 points to an average of $29.03 (low $19.33, high $47.22) — a potential gain of +71% on today's $16.99. Buyers look set to stay in control over this stretch.
In 2032, CAI is projected to trade between $19.87 and $51.13, averaging $30.66 — a potential gain of +80% from today's $16.99. That is up +6% on the projected 2031 average. Momentum favours further upside here.
Caris Life Sciences, Inc.'s 2033 outlook centres on $29.96, within a $18.92 to $51.08 range. That is -2% versus the projected 2032 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, CAI could reach as high as $53.55, with a base case around $30.77 and support toward $18.95 — roughly +81% from $16.99. Momentum favours further upside here.
Expect CAI to range from $19.42 to $57.28 through 2035. The $32.29 average target implies a +90% move from current prices. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The CAI price prediction for 2040 points to an average of $48.68 (low $26.19, high $93.40) — a potential gain of +187% on today's $16.99. Momentum favours further upside here.
In 2050, CAI is projected to trade between $41.83 and $199.51, averaging $92.95 — a potential gain of +447% from today's $16.99. That is up +91% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in CAI today (≈ 58.858152 CAI) could be worth
$5,470.6
+$4,470.6 (+447%) by 2050 · US Dollar
Based on the average projected CAI price of $92.95 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CAIwould be worth at today's price.
$1,000 invested in CAI on Jul 10, 2025 (≈ 37.565739 CAI) would be worth
$638.24
-$361.76 (-36.2%) today · 0.64× · US Dollar
Based on a CAI entry price of $26.62 vs. today's $16.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.3 | $928.42 | -7.2% |
| 1 month ago | $17.16 | $990.09 | -1.0% |
| 3 months ago | $18.05 | $941.27 | -5.9% |
| 6 months ago | $25.6 | $663.67 | -33.6% |
| 1 year ago | $26.62 | $638.24 | -36.2% |
| All time (1.1y) ago | $28 | $606.79 | -39.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CAI forecast.
Our base-case forecast reaches $34.00 around 2040.
Implied market cap at $34.00: $9.61B
The multi-year forecast depicts a bullish trajectory with rising averages and sizable returns. In 2026 the avg is $17.32 with 0% ROI, moving to 2027 avg $18.25 (ROI 5.4%), 2028 avg $20.58 (ROI 18.8%), and 2029 avg $24.77 (ROI 43%), with sentiment remaining NEUTRAL to BULLISH. By 2030 the avg is $27.29 (ROI 57.6%), 2031 $31.29 (80.6%), 2032 $33.20 (91.7%), 2033 $32.53 (87.8%), 2034 $33.83 (95.3%), and 2035 $35.88 (107.2%), all labeled BULLISH.
Looking further out, 2040 shows an avg of $54.68 (ROI 215.7%), and 2050 projects an avg of $107.21 with a max of $228.54 (ROI 519%), continuing the bullish stance. These figures illustrate a steady, long-run rise in value, but they are estimates and not guarantees. Market conditions and other uncertainties can affect outcomes.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg price of $27.29, with a min of $18.78 and a max of $43.01, and a ROI of 57.6%, with bullish sentiment.
The forecast shows a bullish trajectory from 2029 onward, with rising averages and ROIs through 2050 (e.g., 2029 ROI 43%, 2030 57.6%, 2031 80.6%, 2032 91.7%, 2033 87.8%, 2034 95.3%, 2035 107.2%, 2040 215.7%, 2050 519%). These are estimates, not guarantees.
Yes. The 2050 max is $228.54 and the 2050 avg is $107.21, indicating the potential to exceed $100 according to the forecast.
CAI's current price is $17.32 and its market cap is $4.9B.
RSI28 is 50 with a 30-day range of $14.20 to $21.12. The SMA50 is $17.24 and the SMA200 is $22.91, with support at $15.38 and resistance at $18.75.
Caris Life Sciences, Inc. Community Discussion
0Share your Caris Life Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.